Optimizing the role of Thiopurines therapy in Inflammatory Bowel Disease
- Conditions
- Health Condition 1: K50-K52- Noninfective enteritis and colitis
- Registration Number
- CTRI/2020/05/024976
- Lead Sponsor
- Shailesh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients with a definite diagnosis of Ulcerative Colitis (UC) or Crohnâ??s Disease (CD) being initiated on azathioprine/6-mercaptopurine/ 6Tioguanine therapy (designated as thiopurine (TP) therapy) as per standard accepted criteria will be included.
1. Patients with CD or UC on biologicals, or immunosuppressives other than thiopurines
2. Subjects who have undergone total procto-coloctomy for UC
3. Evidence of colorectal dysplasia or malignancies
4. Patients in whom bowel surgery appears to be imminent
5. Congenital or acquired immunodeficiency, especially known HIV infections, or evidence
of other immuno-compromised states
6. Patients ineligible in any way for TP therapy e. g. known intolerance to the drug
7. Patients not providing written informed consent for inclusion
8. Planning to conceive in 17weeks after initiation of therapy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method